HeartBeam, Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership, and institutional investors. The funds will be used to accelerate commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of artificial intelligence capabilities, and for general corporate purposes.
The offering underscores confidence in HeartBeam's platform technology, which aims to revolutionize cardiac monitoring. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025, enables cable-free collection of ECG signals from three non-coplanar directions. These signals can be synthesized into a traditional 12-lead ECG, allowing physicians to monitor cardiac health trends and detect acute conditions outside of medical facilities. This approach could significantly improve access to cardiac diagnostics and reduce time to treatment for patients experiencing heart attacks.
With over 20 issued patents related to its technology, HeartBeam is positioned to address a critical need in cardiovascular care. The extended-wear patch and heart attack detection technologies under development could provide continuous monitoring and early warning for high-risk patients. The infusion of capital will support regulatory submissions, manufacturing scale-up, and sales and marketing efforts to drive adoption among healthcare providers.
HeartBeam's technology has the potential to redefine cardiac health management by enabling portable, intelligent monitoring that can be used wherever the patient is. The company's focus on synthesizing 12-lead ECG signals from a compact device addresses limitations of traditional ECG systems, which are often cumbersome and require clinical settings. If successful, HeartBeam's solutions could reduce healthcare costs and improve outcomes for millions of patients with cardiovascular disease.
The closing of this offering marks a significant milestone for HeartBeam as it transitions from development to commercialization. The company's next steps will be closely watched by investors and the medical community as it seeks to bring its innovative cardiac monitoring platform to market. For more details, the full press release is available at https://ibn.fm/9iNYY.
